DPP-4抑制剂沙格列汀对2型糖尿病患者血清NO、ET-1含量的影响  

Effect of DPP-4 inhibitor Saxagliptin on release of NO and ET-1 secreted in patients with type Ⅱ diabetes

作　　者：韩白玉[1] 卢岚敏[1] 张丽萍[1] 范忠义[1] 

机构地区：[1]解放军第264医院内分泌科,山西太原030001

出　　处：《临床军医杂志》2014年第9期888-889,893,共3页Clinical Journal of Medical Officers

摘　　要：目的观察二肽基肽酶-4(DPP-4)抑制剂沙格列汀对2型糖尿病(T2DM)患者血清一氧化氮(NO)及内皮素-1(ET-1)含量的影响。方法将80例新诊断的T2DM患者采用计算机完全随机分为沙格列汀组和对照组各40例。沙格列汀组患者给予运动饮食改善等糖尿病基础治疗,同时加用沙格列汀5 mg/d,对照组给予运动饮食改善等糖尿病基础治疗和安慰剂。治疗12周后观察两组患者治疗前后血清NO、ET-1变化。结果 DPP-4抑制剂沙格列汀可以升高T2DM患者血清NO水平(P<0.05),同时降低血清ET-1水平(P<0.05)。治疗过程中沙格列汀组出现1例低血糖反应。结论 DPP-4抑制剂沙格列汀可调节T2DM患者血管内皮分泌NO/ET-1的平衡。Objective To investigate the effect of DPP-4 inhibitor Saxagliptin on the release of nitric oxide （NO） and endothelin-1 （ ET-1 ） secreted in patients with type 2 diabetes. Methods A total of 80 newly diagnosed patients with type 2 diabetes were ran- domly divided into two groups （ n = 40/group）. Trial group was treated with exercise-diet therapy and Saxagliptin at 5 mg/d, and control group with exercise-diet therapy and placebo. NO and ET-1 levels in serum were evaluated after 12 weeks＇ treatment. Results Compared with that of the control group, the level of serum NO of the trial group was obviously elevated （ P 〈 0.05 ） and the level of serum ET-1 of the trial group was obviously lowered （ P 〈 0.05 ）. Conclusion Saxagliptin may improve the release of NO and inhibit the release of ET-1 in patients with type 2 diabetes.

关 键 词：糖尿病 沙格列汀 一氧化氮 内皮素 

分 类 号：R587.1[医药卫生—内分泌]